Projects per year
Personal profile
Biography
I am a dedicated and compassionate medical oncologist with a particular interest in genitourinary and
gastrointestinal cancers. I have five years of Consultant Medical Oncology experience, predominantly treating genitourinary and lower gastrointestinal cancers. I have a particularly strong research background, with extensive experience as an investigator in clinical trials and translational research. I have completed a Masters in Clinical Epidemiology and have submitted a PhD in translational prostate cancer. Through working at the NHMRC Clinical Trials Centre and for the ANZUP Trials Group, I have developed trial management experience in large Phase 2 and 3 trials and have established solid research connections and collaborative networks.
Fingerprint
Dive into the research topics where Alison Zhang is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
SURF-301: CTU: A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)
Zhang, A., Chester, C. & Chapman, N.
31/10/22 → 28/09/27
Project: Research
-
CTU: a Phase 2, multicenter, randomized, open label, parallel-arm, umbrella study of avelumab (MSB0010718C) in combination with other anti tumor agents as a maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma whose disease did not progress with 1L platinum-containing chemotherapy
Zhang, A., Chester, C. & Chapman, N.
30/09/22 → 8/07/27
Project: Research
-
IMMU-132-11: CTU A PHASE 2 OPEN-LABEL STUDY OF SACITUZUMAB GOVITECAN (IMMU-132) IN SUBJECTS WITH METASTATIC SOLID TUMORS
Zhang, A., Chapman, N. & Chester, C.
7/07/22 → 15/06/27
Project: Research
-
iPredict: A Phase IIB, Open Label, Study of 89Zr-Df-Crefmirlimab PET/CT in Subjects with Selected Advanced or Metastatic Malignancies including Melanoma, Merkel Cell, Renal Cell and Non-Small Cell Lung Cancers, 2 scheduled to Receive Standard-of-Care Immunotherapy (IOT) as a Single Agent or Combination, to Predict Response to Therapy
Zhang, A., Chester, C. & Chapman, N.
21/01/22 → 9/12/26
Project: Research
Research Outputs
- 13 Article
-
Modulation of plasma lipidomic profiles in metastatic castration-resistant prostate cancer by simvastatin
Mak, B., Lin, H-M., Duong, T., Mahon, K. L., Joshua, A. M., Stockler, M. R., Gurney, H., Parnis, F., Zhang, A., Scheinberg, T., Wittert, G., Butler, L. M., Sullivan, D., Hoy, A. J., Meikle, P. J. & Horvath, L. G., 30 Sep 2022, In: Cancers. 14, 19, p. 1-15 15 p., 4792.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)6 Downloads (Pure) -
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
Buteau, J. P., Martin, A. J., Emmett, L., Iravani, A., Sandhu, S., Joshua, A. M., Francis, R. J., Zhang, A. Y., Scott, A. M., Lee, S-T., Azad, A. A., McJannett, M. M., Stockler, M. R., Williams, S. G., Davis, I. D., Hofman, M. S. & TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Nov 2022, In: The Lancet Oncology. 23, 11, p. 1389-1397 9 p.Research output: Contribution to journal › Article › peer-review
16 Citations (Scopus) -
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., Francis, R. J., Gedye, C., Rutherford, N. K., Weickhardt, A., Scott, A. M., Lee, S-T., Kwan, E. M., Azad, A. A., Ramdave, S., Redfern, A. D., & 14 others, 27 Feb 2021, In: Lancet. 397, 10276, p. 797-804 8 p.Research output: Contribution to journal › Article › peer-review
340 Citations (Scopus) -
Evaluation of a mainstream model of genetic testing for men with prostate cancer
Scheinberg, T., Goodwin, A., Ip, E., Linton, A., Mak, B., Smith, D. P., Stockler, M. R., Strach, M. C., Tran, B., Young, A. L., Zhang, A. Y., Mahon, K. L. & Horvath, L. G., 1 Feb 2021, In: JCO Oncology Practice. 17, 2, p. e204-e216 14 p.Research output: Contribution to journal › Article › peer-review
16 Citations (Scopus) -
Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy
ENZAMET Trial Investigators & The Australian and New Zealand Urogenital Prostate Cancer Trials Group (ANZUP), Sep 2021, In: European Urology. 80, 3, p. 275-279 5 p.Research output: Contribution to journal › Article › peer-review
18 Citations (Scopus)
Prizes
Activities
- 7 Presentation
-
An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy
Alison Zhang (Speaker)
8 Feb 2018 → 10 Feb 2018Activity: Talk or presentation › Presentation
-
Chemotherapy reduces time to development of radiation-induced sarcomas
Alison Zhang (Speaker)
2 Jun 2017 → 6 Jun 2017Activity: Talk or presentation › Presentation
-
A prospective multi-centre Phase III validation study of AZGP1 as a biomarker in localized prostate cancer
Alison Zhang (Speaker)
13 Feb 2017 → 15 Feb 2017Activity: Talk or presentation › Presentation
-
Toxicity-adjusted dose of sunitinib gives low-intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer
Alison Zhang (Speaker)
30 May 2014 → 3 Jun 2014Activity: Talk or presentation › Presentation
-
Metformin to preventing androgen deprivation therapy-induced insulin resistance and the metabolic syndrome
Alison Zhang (Speaker)
27 Sep 2013 → 1 Oct 2013Activity: Talk or presentation › Presentation